In vitro 1,25-dihydroxycholecalciferol (1,25(0H)2D3) decreased levels of preproparathyroid(preproPTH) hormone mRNA. We have now pursued these studies in vivo in the rat. Rats were administered vitamin D metabolites i.p. and the levels of preproPTH mRNA were determined in excised parathyroidthyroid glands by blot hybridization. PreproPTH mRNA levels were <4% of basal at 48 h after 100 pmol 1,25(OH)2D3, with no increase in serum calcium. Gel blots showed that 1,25(OH)2D3 decreased preproPTH mRNA levels without any change in its size (833 basepair). Microdissected parathyroids after 1,25(0H)2D3 (100 pmol) showed mRNA levels for preproPTH were 40±8% of controls, but for f-actin were 100% of controls.
Introduction
Parathyroid hormone (PTH)' and 1,25-dihydroxyvitamin D act together to regulate calcium homeostasis. PTH is trophic to 1,25-dihydroxyvitamin D synthesis both directly and via its effect in lowering renal tubular phosphorus. Both hormones increase serum calcium concentration, which in turn decreases the secretion of PTH (1, 2) .
There is also accumulating evidence that 1,25-dihydroxycholecalciferol (1,25(OH)2D3) itself has a direct effect on PTH synthesis and secretion. 1,25(OH)2D3 acts on target cells by mechanisms similar to those ofthe classic steroid hormones (3) . Parathyroid cells have stereospecific, high affinity receptors for 1,25(OH)2D3 (4, 5) similar to the receptors found in the classic target sites for 1,25(OH)2D3, namely intestine and bone (6, 7) . Moreover, after intravenous administration of[3H]-1,25(OH)2D3 to chicks and rats, there is marked accumulation ofradioactivity in the parathyroid nuclei (8, 9) . These data suggest that the parathyroid gland is a target organ for 1,25(OH)2D3.
Silver et al., using isolated bovine parathyroid cells in primary culture, showed in vitro that l,25(0H)2D3 reduced preproPTH mRNA levels by 50% at 48 h (10). Cantley et al. showed that this reduced preproPTH mRNA level correlated with a similar reduction in PTH secretion by the cells at the corresponding times, with no effect of 1,25(0H)2D3 on PTH secretion at shorter time intervals (11) . Thus in vitro 1,25(QH)2D3 has no effect on secretion of preformed hormone, but decreases the levels of preproPTH mRNA, probably by acting on DNA transcription.
However, to establish that this in vitro effect of 1,25(OH)2D3
occurs under physiologically relevant conditions, it needed to be studied in vivo. In this report we have demonstrated in vivo in the rat that 1,25(OH)2D3 dramatically decreased parathyroid gland preproPTH mRNA over 3-48 h with no change in serum calcium, and that 1,25(OH)2D3 directly inhibits PTH gene transcription.
Methods
Animals. Male Hebrew University strain rats (150-180 g) were maintained on a normal diet and injected intraperitoneally with vitamin D metabolites dissolved in propylene glycol (100 ul). At timed intervals the thyroids with attached parathyroids were excised under pentobarbital anesthesia, and blood samples taken. The excised tissue was immediately frozen in liquid nitrogen and stored at -20'C until extraction. In some experiments parathyroids were microdissected from the thyroids in a petri dish positioned in a Lucite chamber perfused continuously with a cooling fluid to yield a constant temperature (12) . The isolated parathyroids were then frozen as before.
Measurement ofcellular mRNA levels. Total RNA was prepared from either thyroid-parathyroid or microdissected parathyroid tissue by homogenation in guanidium thiocyanate followed by deproteinization using guanidine hydrochloride and ethanol precipitation (13) . Total Hybridization. Rat preproPTH cDNA clone in plasmid PT43 was used (15) . The gel-purified restriction fragments (Kpn I, Pst I) containing preproPTH cDNA (833 basepair [bp]) were labeled by nick-translation to a specific activity of 2-5 X 10' cpm/4g (16) .
Hybridization was carried out over night at 420C, filters were exposed to x-ray film for 24 h, and the film was scanned with a densitometer.
Nuclear transcription and RNA isolation. Nuclei were purified for in vitro transcription as described (l7 
Results
We first examined the tissue specificity ofthe preproPTH cDNA clone and showed that there was no hybridization with RNA extracts from rat liver, muscle brain, or thyroid. When rat parathyroid-thyroid tissue RNA was hybridized with the preproPTH cDNA clone, there was strong hybridization, which varied appropriately with serial dilution of each sample ( Fig. 1, inset) , and was quantitated by densitometric scanning. When l,25(0H)2D3 at 50 or 100 pmol was administered to rats at 0-48 h before removing the parathyroid-thyroid tissue, relative hybridization with the preproPTH cDNA probe was markedly suppressed (Fig. 1 ). After 50 pmol 1,25(OH)2D3, levels of preproPTH mRNA were unchanged at 3 h, but <50% of basal at 6 h, and <20% at 24 h. Rats given 100 pmol 1,25(OH)2D3 had reduced preproPTH mRNA levels at 3 h, which continued to decrease until 48 h when they were similar to rats given 50 pmol 1,25(OH)2D3 who had been given a second injection at 24 h (Fig. 1) . Repeat experiments at various times (e.g., 3, 6 , and 24 h) showed virtually identical results. The serum calciums were not elevated at sacrifice in any of the groups of rats, e.g., 2.85±0.05 mm calcium 0-48 h after 100 pmol 1,25(OH)2D3.
To determine whether 1,25(0H)2D3 influenced mRNA processing as well as mRNA levels, a Northern blot was performed. Total RNA was run on gel blots and then hybridized with 32p-labeled preproPTH cDNA. The preproPH mRNA from control rats (Fig. 2 , lanes I and 2) and 1,25(OH)2D3 (100 pmol)-treated rats (Fig. 2, lanes 3 and 4) was 833 bp, which corresponded to the size ofthe purified preproPTH cDNA fragment (Fig. 2, 6). 1,25(OHhD3 clearly decreased preproPTH mRNA in parathyroid tissue from a single rat (Fig. 2, lane 3) , and parathyroid tissue combined from two rats (Fig. 2, Newly synthesized mRNA for preproPTH and fi-actin were quantitated by hybridization to the immobilized cDNA.
PreproPTH mRNA synthesis for 1,25(OH)2D3-treated rats was 10% of control, whereas f3-actin mRNA for 1,25(QH)2D3-treated rats was 100% ofcontrol (Fig. 5) . The control and 1,25(OH)2D3-treated nuclear preparations synthesized similar amounts oftotal mRNA as seen in the identical amounts of(B-actin mRNA synthesized, as well as identical amounts of thyroglobulin mRNA (result not shown). pBR 322 was used as a negative control. Discussion one control rat (Fig. 2, lane 1) or two control rats combined. There was no hybridization with rat liver (Fig. 2, lane 5) .
To test the specificity of the effect of 1,25(OH)2D3 on preproPTH mRNA, the cellular concentration of mRNA for an unrelated protein, fl-actin was studied. The level of preproPTH mRNA in microdissected parathyroids 24 h after an injection of 100 pmol 1,25(OH)2D3 was reduced by 60% as compared with control rats (Fig. 3) , 1,25(OH)2D3 had no effect on the levels of ,B-actin mRNA (Fig. 3) .
A vitamin D metabolite dose response study showed that the effect of 1,25(OH)2D3 in reducing preproPTH mRNA was evident even at 12.5 pmol with little change from 50 to 250 pmol (Fig. 4) The results of this in vivo study confirm the previous in vitro study that vitamin D metabolites regulate the levels of mRNA for preproPTH in the parathyroid gland (10). The present in vivo study demonstrated that after injection of physiological amounts of 1,25(OH)2D3 to normal rats that did not raise serum calcium, there was a dramatic reduction in preproPTH mRNA levels. The effect of 1,25(OH)2D3 was clearly evident at 3 h after injection and was even more marked at later time intervals (Fig. 1) .
The level of preproPTH mRNA was <1% ofbasal 48 h after 100 pmol 1,25(OH)2D3, demonstrating a remarkably potent negative control. Vitamin D3 itself did not reduce preproPTH mRNA levels at all, whereas 25(OH)D3 was only minimally effective (20% reduction) at pharmacological doses (500 pmol) (Fig. 4) and vitamin D3 at 500 pmol caused hypercalcemia (serum calcium 3.0±0.05 mmol/liter) with no effect on preproPTH mRNA levels.
A Northern blot showed that the preproPTH mRNA was 833 bp and that the preproPTH mRNA from both control and l,25(OH)2D3-treated rats had the same electrophoretic mobility with no larger mRNA fragments after 1,25(OH)2D3 (Fig. 2) . The effect of 1,25(OH)2D3 was therefore on PTH gene transcription or preproPTH mRNA half-life and not on mRNA processing. The decrease in preproPTH mRNA levels caused by 1,25(OH)2D3 was clearly demonstrated in the Northern blot.
The specificity of the 1,25(0HhD3 effect on preproPTH mRNA was studied by comparing the levels of mRNA for preproPTH and fl-actin in the same parathyroid gland RNA extracts. While microdissected rat parathyroids' mRNA for preproPTH was reduced 60% by a single 1,25(OH)2D3 injection (100 pmol), there was no change in fl-actin mRNA. These results confirm the specificity of the 1,25(OH)2D3 effect that had been shown in vitro.
To determine whether the 1,25(OH)2D3 regulation of preproPTH mRNA levels was mediated transcriptionally, we performed nuclear transcription run-off experiments. In this system RNA synthesis consists ofelongation and completion of previously initiated RNA molecules. Thus, the labeling of nascent RNA in vitro accurately reflects the RNA initiation that occurred in vivo. There was a dramatic reduction in PTH transcription in 1,25(OH)2D3-treated rats to 10% ofcontrol rats (Fig.   5 ), whereas f3-actin transcription in the same 1,25(OH)2D3-treated rats was 100% of control. pBR322 plasmid did not hybridize. This confirms the specificity of the PTH and ft-actin hybridization. These in vivo results now establish that vitamin D metabolites regulate preproPTH mRNA levels through its effect on PTH gene transcription, and that 1,25(OH)2D3 is a major factor in the regulation of the PTH gene. There are cytoplasmic receptors for 1,25(0H4)D3 in parathyroid cells (4, 5) and 1,25(OH)2D3 accumulates in parathyroid nuclei (6, 7) . The parathyroid cell is therefore an important target organ for 1,25(OH)2D3. It is postulated that steroid hormones enter cells by facilitated diffusion and bind to the specific receptor protein, initiating an allosteric alteration of the complex, which then binds to chromosomal DNA with high affinity (19) . The modulation of specific gene transcription is dependent upon sequences in their 5' flanking regions that preferentially bind receptors (19) . The specific binding sites for the 1,25(OH)2D3 receptor complex that regulates preproPTH gene transcription is currently being studied.
There is no parathyroid cell line but the rat pituitary cell line (GH4C1) has a 1,25(OH)2D3 cytosol-binding protein and BR322 Figure 5 . Nuclear transcription run-offs for PTH and fl-actin of control and 1,25(0H)2D3-treated rats. 18 control rats and 18 rats treated with 1,25(OH)2D3 100 pmol i.p. 24 h earlier were used.
The parathyroid-thyroid tissue from the 18 control rats was pooled and that from the 1,25(OH)2D3-treated rats was pooled, and nuclei isolated from each of the two preparations. Newly synthesized mRNA sequences were quantitated by hybridization to immobilized cDNA for preproPTH (in duplicate) and f-actin. pBR 322 plasmid was a nonspecific control (see Methods).
responds to added 1,25(OH)2D3 by a marked increase in prolactin mRNA and prolactin synthesis, with no increase in growth hormone mRNA or synthesis (20) . Extracellular calcium only increased prolactin mRNA when 1,25(OH)2D3 was present, and had no effect when no 1,25(OHhD3 was added, demonstrating an interesting interaction between cellular 1,25(0H)2D3 and calcium. Moreover, preliminary evidence from Kronenberg's laboratory using the same cell line transfected with the human PTH gene showed that added 1,25(0HhD3 (l0-' M) significantly reduced PTH mRNA levels (21) . These data all indicate that the 1,25(OH)2D3 effect on PTH is on PTH gene transcription.
The concentration of serum-ionized calcium is the major factor that controls the secretion of PTH; low calcium stimulates and high calcium suppresses PTH secretion (1, 2 would be translated into lower levels of secreted PTH. This question has been widely studied both in vitro and in vivo with confficting results. In vitro, in the short term incubations (0.5-4 h) most studies showed that 1,25(OH)2D3 had no effect on PTH secretion (11, 25) , but for longer incubations (e.g., 24-48 h) there is a dose-dependent reduction in PTH secretion (11, 26) that closely paralleled levels ofpreproPTH mRNA (1 1). The 1,25(OH)2D3 effect on PTH secretion might therefore be a consequence ofthe decreased preproPTH mRNA and subsequently decreased PTH synthesis. Chertow et al. (27) found in vivo decreased serum PTH in rats given 1,25(OH)2D3, results not confirmed in the rat (28) or in humans (29). In situations of parathyroid hyperplasia (e.g., chronic renal failure) there is an increased set-point for calcium suppression of PTH release (30) . Calcium set-point is defined as the calcium concentration halfmaximally suppressing PTH release. Slatopolsky et al. showed that in chronic renal failure patients on chronic intermittent hemodialysis that intravenous 1,25(OH)2D3 given after dialyses markedly suppressed (70%) serum PTH levels, whereas raising the serum calcium by oral calcium only decreased iPTH by 25% (31) . Therefore, even where there is an increased parathyroid mass with altered set-point, as in chronic renal failure, 1,25(OH)2D3 is an important factor in controlling serum PTH levels. In acute renal failure, where there is no parathyroid hyperpIasia, Madson et al. showed that intravenous 1,25(OH)2D3 significantly reduced serum PTH without any change in serum calcium (32) . These human studies used intravenous 1,25-(OH)2D3, which would provide a greater delivery of the sterol to target organs such as the parathyroid, than oral 1,25(OH)2D3.
When 1,25(OH)2D3 is given orally it markedly increases calcium absorption and is itselfpartially metabolized in the intestine (3). The 1,25(OH)2D3 given intraperitoneally to the rats in the present study is comparable to intravenous 1,25(OH)2D3, and would be handled like 1,25(OH)2D3 produced endogenously. 1,25(OH)2D3 therefore appears to be the major factor controlling PTH gene transcription, as shown by in vitro studies (10) and the present in vivo studies, and this is manifested by its effect in vivo on serum PTH levels. Calcium is the major determinant of parathyroid activity by its control of PTH secretion and catabolism. In addition the parathyroid gland responds to chronically low levels of extracellular calcium (e.g., days or weeks) by hypertrophy and proliferation of parathyroid cells with a tremendous increase in total PTH production (1, 2). Whereas calcium controls parathyroid cell replication and PTH secretion, the control of parathyroid transcription and hence PTH production by the individual parathyroid cells may be determined by 1,25(OH)2D3, as the present studies show. Whether calcium has any role in the regulation of the parathyroid gene is currently being studied.
In summary, PTH increases renal 1,25(OH)2D3 synthesis and both hormones then act to raise serum calcium, which in turn decreases PTH secretion. 1,25(OH)2D3 itselfdecreases PTH synthesis and hence serum PTH levels thus completing the endocrinological loop.
